BIOGRAPHICAL SKETCH
NAME
POSITION TITLE
Peter C. Harris
Professor of Biochemistry/Molecular Biology and
Medicine
eRA COMMONS USER NAME
PCHARRIS
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
DEGREE
YEAR(s)
FIELD OF STUDY
(If applicable)
University of East Anglia, Norwich, England
University of Glasgow, Glasgow, Scotland
Harvard Med School/Children's Hosp, Boston, MA
Institute of Molecular Medicine, Oxford, England
B.Sc.
Ph.D.
1981
1984
1984 - 87
1987 - 90
Genetics
Medical Genetics
Pediatrics/Med (Genetics)
Molecular Medicine
A. POSITIONS AND HONORS
1990-1994
Medical Research Council Non-Clinical Scientist (Assistant Professor), Institute of
Molecular Medicine, Oxford
1994-1999
Medical Research Council Senior Scientist (Associate Professor), Institute of Molecular
Medicine, Oxford
1998-1999
University Research Lecturer, Clinical Medicine, University of Oxford, Oxford
1999
Professor of Medical Genetics, Clinical Medicine, University of Oxford, Oxford
1999-2003
Senior Associate Consultant, Division of Nephrology, Mayo Clinic & Fnd, Rochester, MN
2003-present
Consultant, Division of Nephrology, Mayo Clinic and Foundation, Rochester, MN
2000-present
Professor of Biochemistry/Molecular Biology and Medicine, Mayo Medical School
1998
Program Committee, American Society of Nephrology Annual Meeting
1999
Editorial Board, Human Molecular Genetics
2000, 2001, 2002, 2003, 2007, 2009 (x3) - NIDDK Ad hoc reviewer
2003-2007
NIDDK CMBK Member
2001-2005
Editorial Board, Journal American Society of Nephrology
2003
Inaugural Lillian Jean Kaplan International Prize for Advancement in the Understanding of
Polycystic Kidney Disease (PKD)
2004-present
Member, Scientific Advisory Committee, Polycystic Kidney Disease Foundation
2004-2006
Member, Basic Science Committee, American Society of Nephrology
2006-present
Graduate Program Director, Biochemistry/Molecular Biology Track Mayo Graduate School
2008
American Society of Nephrology, Homer W. Smith Award
B. SELECTED PEER-REVIEWED PUBLICATIONS (chronological order). (Total articles, reviews = 142)
1. The European Polycystic Kidney Disease Consortium, (Harris, P.C., corresponding author). The
polycystic kidney disease 1 gene encodes a 14kb transcript and lies within a duplicated region on
chromosome 16. Cell 1994; 77:881-894.
2. Hughes, J., Ward, C.J., Peral, B., Aspinwall, R., Clark, K., San Millán, J.L., Gamble, V. & Harris, P.C. The
polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains.
Nat Genet 1995; 10:151-160.
3. Ward, C., Turley, H., Ong, A.C.M., Comley, M., Biddolph, S., Chetty, R., Ratcliffe, P.J., Gatter, K. &
Harris, P.C. Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal,
adult, and polycystic kidney. Proc Natl Acad Sci, USA 1996; 93:1524-1528.
4. Ward C. J., Hogan, M. C., Rossetti, S., Walker, D., Sneddon, T., Wang, X., Kubly, V., Cunningham, J. M.,
Bacallao, R., Ishibashi, M., Milliner, D. S., Torres, V. E., Harris, P.C. The gene mutated in autosomal
recessive polycystic kidney disease encodes a large, receptor-like protein. Nature Genet,2002;30:259-269
5. Rossetti, S., Burton, S., Strmecki, L., Pond, G. R., San Millán, J. L., Zerres, K., Barratt, T. M., Ozen, S.,
Torres, V. E., Bergstralh, E. J., Winearls, C. G., Harris, P.C. The position of the polycystic kidney disease
1 (PKD1) mutation correlates with the severity of renal disease. J Am Soc Nephrol, 2002; 13:1230-1237.
6. Rossetti, S., Burton, S., Strmecki, L., Pond, G. R., San Millán, J. L., Zerres, K., Barratt, T. M., Ozen, S.,
Torres, V. E., Bergstralh, E. J., Winearls, C. G., Harris, P.C. The position of the polycystic kidney disease
1 (PKD1) mutation correlates with the severity of renal disease. J Am Soc Nephrol, 2002; 13:1230-7.
7. Hogan MC, Griffin MD, Rossetti S, Torres VE, Ward CJ, Harris P.C. PKHDL1, a homolog of the
autosomal recessive polycystic kidney disease gene, encodes a receptor with inducible T lymphocyte
expression. Hum Mol Genet, 2003; 12:685-698.
8. Rossetti S, Chauveau D, Kubly V, Slezak, J, Saggar-Malik, A, Pei, Y, Ong, ACM, Stewart, F, Watson, ML,
Bergstralh, EJ, Winearls, CG, Torres, V, Harris, P.C. Association of mutation in the polycystic kidney
disease 1 (PKD1) gene and development of a vascular phenotype. Lancet 2003; 361:2196-2201.
9. Ward, C.J., Yuan, D., Masyuk, T.V., Wang, X., Punyashthiti, R., Whelan, S., Bacallao, R., Torra, R.,
LaRusso, N.F., Torres, V.E., Harris, P.C. Cellular and subcellular localization of the ARPKD protein;
fibrocystin is expressed on primary cilia. Hum Mol Genet 2003, 12:2703-2710.
10. Smith UM, Consugar M, Tee LJ, McKee BM, Maina EN, Whelan S, Morgan NV, Goranson E, Gissen P,
Lilliquist S, Aligianis IA, Ward CJ, Pasha S, Punyashthiti R, Malik Sharif S, Batman PA, Bennett CP,
Woods CG, McKeown C, Bucourt M, Miller CA, Cox P, Algazali L, Trembath RC, Torres VE, Attie-Bitach
T, Kelly DA, Maher ER, Gattone VH, Harris, P.C, Johnson CA. The transmembrane protein meckelin
(MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat. Nat Genet. 2006;38:191-196
11. Adeva M, El-Youssef M, Rossetti S, Kamath PS, Kubly V, Milliner DM, King BF, Torres VE, Harris P.C.
Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic
kidney disease (ARPKD). Medicine 2006;85:1-21
12. Nauli, SM, Rossetti, S, Kolb, RJ, Alenghat, FJ, Consugar, MB, Harris, PC, Ingber, DE, Loghman-Adham,
M & Zhou, J: Loss of polycystin-1 in human cyst-lining epithelia leads to ciliary dysfunction. J Am Soc
Nephrol, 17:1015-1025, 2006.
13. Grantham JJ, Torres VE, Chapman AB, Guy-Woodford LM, Bae KT, King BF, Wetzel LH, Baumgarten,
Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zuh F, Miller JP.
Volume evolution: disease progression in autosomal dominant polycystic kidney disease. N Engl J Med
354:2122-2130, 2006.
14. Harris, PC & Torres, VE: Understanding pathogenic mechanisms in polycystic kidney disease provides
clues for therapy. Current Opinion in Nephrology and Hypertension, 15:456-463, 2006.
15. Sutton, KA, Jungnickel, MK, Ward, CJ, Harris, PC & Florman, HM: Functional characterization of
PKDREJ, a male germ cell-restricted polycystin. J Cell Physiol, 209:493-500, 2006.
16. Harris, PC, Bae, K, Rossetti, S, Torres, VE, Grantham, JJ, Chapman, A, Guay-Woodford, L, King, BF,
Wetzel, LH, Baumgarten, D, Kenney, PJ, Consugar, M, Klahr, S, Bennett, WM, Meyers, CM, Zhang, Q,
Thompson, PA, Zhu, F, Miller, JP & CRISP Consortium: Cyst number, but not the rate of cystic growth, is
associated with the mutated gene in ADPKD. JASN, I17:3013-9, 2006.
17. Xu N, Glockner JF, Rossetti S, Babovic-Vuksanovic D, Harris PC, Torres VE. Milder cystic phenotype in
autosomal dominant polycystic kidney disease coexisting with cystic fibrosis. J Neph 19:529-534, 2006.
18. Hiesberger T, Gourley E, Erickson A, Koulen P, Ward CJ, Masyuk TV, LaRusso NF, Harris PC, Igarashi
P. Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca 2+ and
activation of protein kinase C. J Biol Chem 281:34357-64, 2006.
19. Xu C, Rossetti S, Jiang L, Harris PC, Brown-Glaberman U, Wandinger-Ness A, Bacallao RL, Alper SL.
Human ADPKD primary cyst epithelial cells with a novel, single codon deletion in the PKD1 gene exhibit
defective ciliary polycystin localization and loss of flow-induced Ca2+ signaling. Am J Physiol Renal
Physiol. 292:F930-945, 2007.
20. Consugar MB, Kubly VJ, Lager DJ, Hommerding CJ, Wong WC, Bakker E, Gattone II VH, Torres VE,
Breuning MH, Harris PC, Molecular diagnostics of Meckel-Gruber syndrome highlights phenotypic
differences between MKS1 and MKS3. Hum Mol Genet. 121(5):591-599, 2007.
21. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 369:1287-1301,
2007.
22. Rossetti S, Harris PC: Genotype-phenotype correlations in Autosomal Dominant and Autosomal
Recessive Polycystic Kidney Disease (ADPKD and ARPKD). J Am Soc Nephrol [Frontiers in Nephrology]
18(5):1374-1380, 2007.
23. Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, Bennett WM,
Meyers CM, Walker DL, Bae K, Zhang Q, Thompson PA, Miller JP, Harris PC, CRISP. Comprehensive
molecular diagnostics of autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol
18(7):2143-2160, 2007.
24. Woollard JR, Punyashthiti R, Richardson S, Masyuk TV, Whelan S, Huang BQ, Lager DJ, vanDeursen J,
Torres VE, Gattone VH, LaRusso NF, Harris PC, Ward CJ. A mouse model of autosomal recessive
polycystic kidney disease with biliary duct and proximal tubule dilatation. Kidney Int 72:328-336, 2007
25. Yin M, Woollard J, Wang X, Torres VE, Harris PC, Ward CJ, Glaser KJ, Manduca A, Ehman RL.
Quantitative assessment of hepatic fibrosis in an animal model with magnetic resonance elastography.
Magn Reson Med. 2007 58(2):346-353
26. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic
kidney disease. J Am Soc Nephrol. 2008 Jan; 19(1):102-108. PMCID 2391034.
27. Monico CG, Rossetti S, Schwanz HA, Olson JB, Lundquist PA, Dawson DB, Harris PC, Milliner DS.
Comprehensive mutation screening in 55 probands with type 1 primary hyperoxaluria shows feasibility of a
gene-based diagnosis. J Am Soc Nephrol. 2007;18:1905-1914.
28. Rossetti S, Harris PC. Genotype-phenotype correlations in autosomal dominant and autosomal recessive
polycystic kidney disease. J Am Soc Nephrol. 2007;18(5):1374-1380.
29. Parker E, Newby LJ, Sharpe CC, Rossetti S, Streets AJ, Harris PC, O'Hare MJ, Ong AC.
Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf
signalling system. Kidney Int. 2007;72(2):157-165. PMCID: PMC2493387.
30. Gout AM, Harris PC, Rossetti S, Peters D, Breuning M, Henske EP, Koizumi A, Inoue S, Shimizu Y,
Thongnoppakhun W, Yenchitsomanus PT, Deltas C, Sandford R, Torra R, Turco AE, Jeffery S, Fontes M,
Somlo S, Furu LM, Smulders YM, Mercier B, Ferec C, Burtey S, Pei Y, Kalaydjieva L, Bogdanova N,
McCluskey M, Geon LJ, Wouters CH, Reiterova J, Stekrova J, San Millan JL, Aguiari G, Senno LD,
Ravine D. Analysis of published PKD1 gene sequence variants. Nat Genet. 2007;39(4):427-428.
31. Harris PC. Genetic complexity in Joubert syndrome and related disorders. Kidney Int. 2007;72:1421-1423.
32. Grantham JJ, Cook LT, Torres VE, Bost JE, Chapman AB, Harris PC, Bae KT, CRISP. Determinants of
renal volume in autosomal dominant polycystic kidney disease. Kidney Int. 2008 Jan; 73(1):108-116 .
33. Harris PC, Rossetti S. Molecular diagnostics of ADPKD coming of age. Clin J Am Soc Nephrol.
2008;3(1):1-2.
34. Dedoussis GV, Luo Y, Starremans P, Rossetti S, Ramos AJ, Cantiello HF, Katsareli E, Ziroyannis P,
Lamnissou K, Harris PC, Zhou J. Co-inheritance of a PKD1 mutation and homozygous PKD2 variant: a
potential modifier in autosomal dominant polycystic kidney disease. Eur J Clin Invest. 2008;38(3):180-190.
35. Aguiari G, Trimi V, Bogo M, Mangolini A, Szabadkai G, Pinton P, Witzgall R, Harris PC, Borea PA,
Rizzuto R, Del Senno L. Novel role for polycystin-1 in modulating cell proliferation through calcium
oscillations in kidney cells. Cell Prolif. 2008;41:554-573. PMCID: PMC2440503.
36. Aitman TJ, Critser JK, Cuppen E, Dominiczak A, Fernandez-Suarez XM, Flint J, Gauguier D, Geurts AM,
Gould M, Harris PC, Holmdahl R, Hubner N, Izsvak Z, Jacob HJ, Kuramoto T, Kwitek AE, Marrone A,
Mashimo T, Moreno C, Mullins J, Mullins L, Olsson T, Pravenec M, Riley L, Saar K, Serikawa T, Shull JD,
Szpirer C, Twigger SN, Voigt B, Worley K. Progress and prospects in rat genetics: a community view. Nat
Genet. 2008;40(5):516-522.
37. Consugar MB, Wong WC, Lundquist PA, Rossetti, Kubly VJ, Walker DL. Rangel LJ, Aspinwall R, Niaudet
WP, Özen S, David A, Velinov M, Bergstralh EJ, Bae KT, Chapman AB, Guay-Woodord LM, Grantham JJ,
Torres VE, Sampson JR, Dawson BD, Harris PC, CRISP Consortium. Characterization of large
rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene
syndrome. Kidney Int 2008;74(11):1468-79.
38. Hogan MC, Manganelli L, Woollard JR, Masyuk AI, Masyuk TV, Tammachote R, Huang BQ, Leontovich
AA, Beito TG, Madden BJ, Charlesworth MC, Torres VE, LaRusso NF, Harris PC, Ward CJ.
Characterization of PKD protein-positive exosome-like vesicles. J Am Soc Nephrol. 2009;20(2):278-288.
PMCID: PMC2637052.
39. Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van't
Hoff WG, Niaudet WP, Torres VE, Harris PC. Incompletely penetrant PKD1 alleles suggest a role for
gene dosage in cyst initiation in polycystic kidney disease. Kidney Int. 2009; 75(8):848-855 Epub 2009.
40. Wang X, Harris PC, Somlo S, Battle D, Torres VE: Effect of calcium-sensing receptor activation in
models of autosomal recessive or dominant polycystic kidney disease. Nephrol Dial Transpl 2009;
24(2):526-534. PMCID: PMC2639335.
41. Harris PC. 2008 Homer W. Smith Award, Polycystic Kidney disease: insights into pathogenesis from gene
discovery. J Am Soc Nephrol. 2009;20:1188-1198.
42. Tammachote R, Hommerding CJ, Sinders RM, Miller CA, Czarnecki PG, Leightner AC, Salisbury JL,
Ward CJ, Torres VE, Gattone VH 2nd, Harris PC. Ciliary and centrosomal defects associated with
mutation and depletion of the Meckel syndrome genes MKS1 and MKS3. Hum Mol Genet 2009;
18(17):3311-23. PMCID: PMC2733821.
43. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;
76(2):149-168.
44. Streets AJ, Wagner BE, Harris PC, Ward CJ, Ong AC. Homophilic and heterophilic polycystin 1
interactions regulate E-cadherin recruitment and junction assembly in MDCK cells. J. Cell Sci.
2009;122(Pt 9):1410-1417.
45. Xu C, Shmukler BE, Nishimura K, Kaczmarek E, Rossetti S, Harris PC, Wandinger-Ness A, Bacallao RL,
Alper SL. Attenuated, flow-induced ATP release contributes to absence of flow-sensitive, purinergic Cai2+
signaling in human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol. 2009;296(6):F1464-F1476.
PMCID: PMC2692447.
46. Harris PC, Torres, V.E. Polycystic Kidney Disease. Annu Rev Med 2009; 60:321-337.
C. RESEARCH SUPPORT
Ongoing
R01 DK58816 - Harris (PI)
07/01/01 - 06/30/10
NIDDK
ADPKD: Disease Spectrum & Genotype-Phenotype
Objective: This proposal is to study potential genotype/phenotype correlations in ADPKD. Mutations
will be sought in the PKD1 and PKD2 genes by DHPLC and correlations made between the type and
location of changes and the ADPKD phenotype. The mutation mechanism will also be analyzed by
studying ADPKD cystic tissue.
R01 DK59597 Harris (PI)
04/01/02 - 03/31/12
NIDDK
Characterizing the Function of Fibrocystin and Fibrocystin-L
Objective: This proposal is to analyze the function of the ARPKD protein fibrocystin and the related
protein, fibrocystin-L in cellular and whole animal systems.
U01DK56957
02/01/06-03/31/11
NIDDK
PKD, Innovative Imaging to Assess Progression (PCC) - Torres (PI)
Objective: The major goal of this project is to ascertain the value of MR measurements of renal volumes
as surrogate markers of disease progression in ADPKD
R01 DK68581 (Gattone (PI); Harris: subcontract PI) 04/01/06-03/31/10
NIDDK
Pathogenesis of wpk-induced renal and cerebral pathology – No cost extension
Objective: The aims of this proposal are to characterize the Wpk gene and protein product.
New proposal is replacement of this grant.
Ancillary to DK62410- Harris (PI on Ancillary)
08/01/08-07/31/11
NIDDK
Mutation Screening of the PKD1 and PKD2 genes in the HALT population
Direct Sequencing will be used to identify mutations in the HALT PKD ADPKD population
PKDF#12 – Harris (PI)
07/01/06-03/31/10
PKD Foundation
Maintenance of the ADPKD mutation database
Objective: Development of the International ADPKD database
Pending
R01 DK079856 Harris (PI)
04/01/10-03/31/15
NIDDK
Identifying Genetic Modifiers of severity in the CRISP ADPKD population
Objective: Use a genome wide association study to identify genetic factors associated with the severity of
disease in ADPKD
R01 DK58816 -10 Harris (PI)
04/01/10-03/31/15
NIDDK
ADPKD: Disease Spectrum & Genotype-Phenotype
Objective: Patients where no PKD1 and PKD2 mutation has been identified will be a focus of this study.
In addition, that role that completely penetrant alleles play in modulating the severity of disease will be
clarified.